NYSE · HAE
Haemonetics Corporation
$119.79+$1.47 (+1.24%)
Haemonetics Corporation’s quoted price sits in the upper half of its reported 52-week range, 3.22% below the high.
Loading market information…
NYSE · ITGR · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Integer Holdings Corporation’s quoted price sits in the upper half of its reported 52-week range, 0.24% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Integer Holdings Corporation’s next earnings report is currently expected on Feb 18, 2027, with estimated earnings per share of $1.75. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Integer Holdings Corporation’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Integer Holdings Corporation functions as a global leader in outsourced medical device manufacturing, maintaining operations across the United States, Puerto Rico, Costa Rica, and other international regions. The company organizes its business into two primary divisions: Medical and Non-Medical. Within its Medical segment, Integer delivers a broad array of devices and components essential for numerous advanced medical procedures. These solutions cater to areas such as interventional cardiology, structural heart conditions, heart failure management, peripheral and neurovascular interventions, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, urology, and gastroenterology. Their extensive product portfolio includes cardiac rhythm management devices like implantable pacemakers, defibrillators, cardiac monitors, leads, and heart failure therapies. They also produce neuromodulation devices, such as implantable spinal cord stimulators, alongside critical components like non-rechargeable batteries, feedthroughs, device enclosures, precision-machined parts, and lead sub-assemblies. Furthermore, Integer provides rechargeable battery systems and chargers. A comprehensive range of surgical instruments and components is also offered for arthroscopic, laparoscopic, and general surgery, encompassing items like harmonic scalpels, various blades and shavers, radio frequency and biopsy probes, trocars, electrocautery components, wound dressings, GERD treatment parts, and phacoemulsification needles. Orthopedic offerings comprise specialized instruments for hip, knee, and spine surgeries, including reamers and chisels, among other general medical technologies. The Non-Medical segment concentrates on developing customized battery power and management systems, along with specialized battery solutions, designed for the energy, military, and environmental sectors. Integer primarily collaborates with multinational original equipment manufacturers (OEMs) and their affiliated subsidiaries, supporting their requirements across diverse markets, including cardiac, neuromodulation, orthopedics, vascular, advanced surgical, and portable medical applications. Established in 1970, Integer Holdings Corporation is headquartered in Plano, Texas.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:32 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q2 2025 | Jul 24, 2025 | $1.55-1.27% vs estimate | $476.49M+2.15% vs estimate |
|---|
| Q1 2025 | Apr 24, 2025 | $1.31+3.15% vs estimate | $437.39M+2.04% vs estimate |
|---|
| Q4 2024 | Feb 20, 2025 | $1.43-2.05% vs estimate | $449.50M+2.84% vs estimate |
|---|
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
THE ANALYST VIEW
16 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 4 contributors · Median target $121.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$119.79+$1.47 (+1.24%)
Haemonetics Corporation’s quoted price sits in the upper half of its reported 52-week range, 3.22% below the high.
$41.25+$0.66 (+1.63%)
Concentra Group Holdings Parent, Inc.’s quoted price sits in the upper half of its reported 52-week range, 0.29% below the high.
$81.25+$0.59 (+0.73%)
LivaNova PLC’s quoted price sits in the upper half of its reported 52-week range, 5.26% below the high.
$4.24-$0.11 (-2.53%)
Recursion Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 27.4% below the high.
$124.34+$2.16 (+1.77%)
Addus HomeCare Corporation’s quoted price sits in the upper half of its reported 52-week range, 0.92% below the high.
$293.30+$7.30 (+2.55%)
UFP Technologies, Inc.’s quoted price sits in the upper half of its reported 52-week range, 13.41% below the high.
$71.18+$0.21 (+0.3%)
Inspire Medical Systems, Inc.’s quoted price sits in the lower half of its reported 52-week range, 51.59% below the high.
$20.30+$0.10 (+0.5%)
PROCEPT BioRobotics Corporation’s quoted price sits in the lower half of its reported 52-week range, 46.73% below the high.
